非布司他治疗伴有高尿酸血症痛风患者的疗效及对相关炎性因子的影响

Efficacy of Febuxostat in Treatment of Gout with Hyperuricemia and Its Effect on Related Inflammatory Factors

目的:探讨非布司他治疗伴有高尿酸血症痛风患者的临床疗效及对血清肿瘤坏死因子-α(TNF-α)、可溶性细胞间黏附分子-1(sICAM-1)及尿酸水平的影响。方法:选取2016年9月-2017年8月本院收治的伴高尿酸血症痛风患者78例为研究对象。按随机数字表法分为观察组和对照组,各39例。对照组给予痛风定片治疗,观察组在对照组基础上给予非布司他片治疗。比较两组患者治疗前后TNF-α、sICAM-1、尿酸水平变化及临床疗效。结果:治疗前两组血清TNF-α、sICAM-1及尿酸水平比较,差异均无统计学意义(P>0.05)。治疗后,两组TNF-α、sICAM-1及尿酸水平均明显降低(P<0.05);观察组治疗后TNF-α、sICAM-1及尿酸水平均明显低于对照组,差异均有统计学意义(P<0.05)。观察组总有效率94.87%明显高于对照组74.36%,差异有统计学意义(P<0.05)。治疗后两组躯体、角色、情绪及社会各项功能评分均显著升高(P<0.05),观察组治疗后躯体、角色、情绪及社会功能评分均显著高于对照组,差异均有统计学意义(P<0.05)。结论:非布司他可显著降低痛风伴高尿酸血症患者血清TNF-α、sICAM-1及尿酸水平,临床疗效确切,值得临床进一步推广应用。

Objective:To investigate the clinical efficacy of Febuxostat in the treatment of gout with hyperuricemia and its effect on serum TNF-α,sICAM-1 and uric acid levels.Method:78 cases of gout with hyperuricemia were selected from September 2016 to August 2017.They were divided into the control group and the observation group by random number table method,39 cases in each group.The control group was treated with Tongfengding tablets,the observation group was treated with Febuxostat on the basis of the control group.TNF-α,sICAM-1,uric acid levels and clinical efficacy of two groups were compared before and after treatment.Result:The serum TNF-α,sICAM-1 and uric acid levels before treatment in the two groups were not statistically significant difference(P>0.05).After treatment,the TNF-α,sICAM-1 and uric acid levels in two groups were significantly decreased(P<0.05);the TNF-α,sICAM-1 and uric acid levels in the observation group were significantly lower than those in the control group(P<0.05).The total effective rate of the observation group was 94.87%significantly higher than that of the control group 74.36%,the difference was statistically significant(P<0.05).After treatment,the scores of body,role,emotion and social function in both groups were significantly higher than before treatment(P<0.05).The scores of body,role,emotion and social function in the observation group were significantly higher than those in the control group(P<0.05).Conclusion:Febuxostat can significantly reduce the levels of serum TNF-α,sICAM-1 and uric acid in patients with hyperuricemia and gout.It has a definite clinical effect and it is worthy of further clinical application.